The liver is the major site of carbohydrate metabolism and lipogenesis. The transcription factor ChREBP is a major mediator of glucose action in the control of hepatic glycolysis and lipogenesis. In the form of heterodimer with its partner Mlx, ChREBP regulates glucose-responsive genes in the liver and a family of genes required for glucose utilization and de novo lipogenesis. Liver-specific inhibition of ChREBP in ob/ob mice can improve hepatic steatosis and insulin resistance. In this review，we introduced the molecular structure, biological function, and regulatory mechanisms of ChREBP, as well as its relevance with metabolic diseases